Publications by authors named "T Vaisitti"
Background: Liver transplantation (LT) is still limited by organ shortage and post-transplant monitoring issues. While machine perfusion techniques allow for improving organ preservation, biomarkers like donor-derived cell-free DNA (dd-cfDNA) and mitochondrial cfDNA (mt-cfDNA) may provide insights into graft injury and viability pre- and post-LT.
Methods: A prospective observational cohort study was conducted on LT recipients (n = 45) to evaluate dd-cfDNA as a biomarker of graft dysfunction during the first 6 months after LT.
Unraveling vulnerabilities in chronic lymphocytic leukemia (CLL) represents a key approach to understand molecular basis for its indolence and a path toward developing tailored therapeutic approaches. In this study, we found that CLL cells are particularly sensitive to the inhibitory action of abundant serum protein, apolipoprotein E (ApoE). Physiological concentrations of ApoE affect CLL cell viability and inhibit CD40-driven proliferation.
View Article and Find Full Text PDFArticle Synopsis
- - Hepatocellular adenomas (HAs) are liver tumors linked to genetic mutations, with this study focusing on a 17-year-old with multiple HAs and a specific pathogenic mutation known to have a dominant negative effect.
- - The study identified additional somatic variants in some HAs and revealed significant transcriptomic changes, including alterations in various metabolic pathways, angiogenesis, and immune response.
- - Findings provide a detailed molecular profile of HAs associated with the identified mutation, paving the way for possible non-surgical treatment strategies by pinpointing new therapeutic targets.
Background: Cystic kidney disease is a heterogeneous group of hereditary and non-hereditary pathologic conditions, associated with the development of renal cysts. These conditions may be present both in children and adults. Cysts can even be observed already during the prenatal age, and pediatric patients with cysts need to be clinically monitored.
View Article and Find Full Text PDFBackground: Endomyocardial biopsy (EMB) is considered the gold-standard method to diagnose rejection after heart transplantation. However, the many disadvantages and potential complications of this test restrict its routine application, particularly in pediatric patients. Donor-derived cell-free DNA (dd-cfDNA), released by the transplanted heart as result of cellular injury, is emerging as a biomarker of tissue damage involved in ischemia/reperfusion injury and posttransplant rejection.
View Article and Find Full Text PDF